Anti-TNFα therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases
Marcus A Gray, Che-Yung Chao, Heidi M Staudacher, Natasha A Kolosky, Nicholas J Talley, Gerald Holtmann, Marcus A Gray, Che-Yung Chao, Heidi M Staudacher, Natasha A Kolosky, Nicholas J Talley, Gerald Holtmann
Abstract
Background: In inflammatory bowel disease (IBD), immune activation with increased circulating TNF-α is linked to the intensity of gastrointestinal symptoms and depression or anxiety. A central feature of depression is cognitive biases linked to negative attributions about self, the world and the future. We aimed to assess the effects of anti-TNFα therapy on the central processing of self-attribution biases and visceral afferent information in patients with Crohn's disease.
Methods: We examined 9 patients with Crohn's disease (age 26.1±10.6. yrs, 5 female, 5 ileocolonic, 2 colonic and 2 ileal disease) during chronic anti-TNFα therapy (5 adalimumab, 4 infliximab). Patients were studied twice in randomized order before and after anti-TNFα administration. On each occasion patients underwent functional magnetic resonance imaging (fMRI) of the brain during a test of implicit attribution biases regarding sickness/health and undertook a standardized nutrient challenge.
Results: Following anti-TNFα treatment, ratings of 'fullness' following nutrient challenge reduced compared to pre-treatment ratings (p<0.05). Reaction times revealed improved processing of self-related and positive health words, consistent with improved implicit sense of wellbeing that correlated with improvements in sensory function after treatment (r = 0.67, p<0.05). Treatment-associated improvements in implicit processing were mirrored by alterations of prefrontal, amygdala, posterior cingulate and visual regions. Between patients, the degree of functional amygdala change was additionally explained by individual differences in attention regulation and body awareness rankings.
Conclusion: In patients with Crohn's disease, anti-TNFα administration reduces visceral sensitivity and improves implicit cognitive-affective biases linked to alterations in limbic (amygdala) function.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. doi:
- Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22(3):752–62. doi:
- Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017.
- Bennebroek Evertsz F, Thijssens NA, Stokkers PC, Grootenhuis MA, Bockting CL, Nieuwkerk PT, et al. Do Inflammatory Bowel Disease patients with anxiety and depressive symptoms receive the care they need? J Crohns Colitis. 2012;6(1):68–76. doi:
- Beigel F, Deml M, Schnitzler F, Breiteneicher S, Goke B, Ochsenkuhn T, et al. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One. 2014;9(6):e99293 doi:
- Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis. 2013;7(9):730–5. doi:
- Mikocka-Walus A, Turnbull D, Moulding N, Wilson I, Andrews JM, Holtmann G. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol. 2008;23(7 Pt 1):1137–43. doi:
- Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review. J Psychosom Res. 2016;87:70–80. doi:
- Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol. 2004;500(1–3):399–411. doi:
- Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi:
- Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66(5):407–14. doi:
- Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Dolan RJ, et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry. 2009;66(5):415–22. doi:
- Eisenberger NI, Inagaki TK, Mashal NM, Irwin MR. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun. 2010;24(4):558–63. doi:
- Beck AT. Thinking and Depression. I. Idiosyncratic Content and Cognitive Distortions. Arch Gen Psychiatry. 1963;9:324–33.
- Beck AT. Depression; causes and treatment. Philadelphia,: University of Pennsylvania Press; 1972. xiv, 370 p. p.
- Dadsetan S, Balzano T, Forteza J, Cabrera-Pastor A, Taoro-Gonzalez L, Hernandez-Rabaza V, et al. Reducing Peripheral Inflammation with Infliximab Reduces Neuroinflammation and Improves Cognition in Rats with Hepatic Encephalopathy. Front Mol Neurosci. 2016;9:106 doi:
- Harrison NA, Voon V, Cercignani M, Cooper EA, Pessiglione M, Critchley HD. A Neurocomputational Account of How Inflammation Enhances Sensitivity to Punishments Versus Rewards. Biol Psychiatry. 2015.
- Martin-Subero M, Anderson G, Kanchanatawan B, Berk M, Maes M. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 2016;21(2):184–98. doi:
- af Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37. doi:
- D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24. doi:
- Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126(6):1593–610.
- Cadahia V, Garcia-Carbonero A, Vivas S, Fuentes D, Nino P, Rebollo P, et al. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practice. Rev Esp Enferm Dig. 2004;96(6):369–74; 74–8.
- Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22(2):101–10. doi:
- Miwa Y, Nishimi A, Nishimi S, Saito M, Tokunaga T, Yanai R, et al. Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone. Eur J Rheumatol. 2014;1(4):147–9. doi:
- Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10. doi:
- Cameron OG. Interoception: the inside story—a model for psychosomatic processes. Psychosom Med. 2001;63(5):697–710.
- Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci. 2002;3(8):655–66. doi:
- Critchley HD, Harrison NA. Visceral influences on brain and behavior. Neuron. 2013;77(4):624–38. doi:
- Porges S. Body Perception Questionnaire Laboratory of Development Assessment, Baltimore, MD, University of Maryland; 1993.
- Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A. The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLoS One. 2012;7(11):e48230 doi:
- Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96(3):804–10.
- Haag S, Talley NJ, Holtmann G. Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut. 2004;53(10):1445–51. doi:
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.
- Spielberger CD. State-trait anxiety inventory: a comprehensive bibliography. 2nd ed Palo Alto, CA (577 College Ave., Palo Alto 94306): Consulting Psychologists Press; 1989. 115 p. p.
- Greenwald AG, McGhee DE, Schwartz JL. Measuring individual differences in implicit cognition: the implicit association test. J Pers Soc Psychol. 1998;74(6):1464–80.
- Greenwald AG, Banaji MR, Rudman LA, Farnham SD, Nosek BA, Mellott DS. A unified theory of implicit attitudes, stereotypes, self-esteem, and self-concept. Psychol Rev. 2002;109(1):3–25.
- Frackowiak RSJ. Human brain function. 2nd ed Amsterdam; Boston: Elsevier Academic Press; 2004. xvi, 1144 p. p.
- Knutson KM, Mah L, Manly CF, Grafman J. Neural correlates of automatic beliefs about gender and race. Hum Brain Mapp. 2007;28(10):915–30. doi:
- Luo Q, Nakic M, Wheatley T, Richell R, Martin A, Blair RJ. The neural basis of implicit moral attitude—an IAT study using event-related fMRI. Neuroimage. 2006;30(4):1449–57. doi:
- Phelps EA, O’Connor KJ, Cunningham WA, Funayama ES, Gatenby JC, Gore JC, et al. Performance on indirect measures of race evaluation predicts amygdala activation. J Cogn Neurosci. 2000;12(5):729–38.
- Healy GF, Boran L, Smeaton AF. Neural Patterns of the Implicit Association Test. Front Hum Neurosci. 2015;9:605 doi:
- Haag S, Senf W, Tagay S, Heuft G, Gerken G, Talley NJ, et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol Motil. 2010;22(3):262–e79. doi:
- Holtmann GT, N. J.; Neufang Hueber J.; Goebell H.,. Comparison of gastric mechanosensory thresholds and maximal tolerance of a liquid meal. Gastroenterology. 1996;110(Suppl. 4):A680.
- Bernstein CN. Psychological Stress and Depression: Risk Factors for IBD? Dig Dis. 2016;34(1–2):58–63. doi:
- Haag S, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, et al. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther. 2007;25(8):973–86. doi:
- Hess A, Roesch J, Saake M, Sergeeva M, Hirschmann S, Neumann H, et al. Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn’s Disease. Gastroenterology. 2015;149(4):864–6. doi:
- Souza GR, Talbot J, Lotufo CM, Cunha FQ, Cunha TM, Ferreira SH. Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci U S A. 2013;110(27):11193–8. doi:
- Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011;108(9):3731–6. doi:
- Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut. 2013;62(10):1456–65. doi:
- Hughes PA, Moretta M, Lim A, Grasby DJ, Bird D, Brierley SM, et al. Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients. Brain Behav Immun. 2014;42:191–203. doi:
- Manabe N, Hata J, Haruma K. [Functional gastrointestinal disorders (FGID): progress in diagnosis and treatments. Topic I. Basic knowledge of functional gastrointestinal disorders (FGID): 5. Gastrointestinal motility dysfunction and viscerosensory dysfunction in patients with FGID]. Nihon Naika Gakkai Zasshi. 2013;102(1):32–9.
- Beck AT. Thinking and Depression. Ii. Theory and Therapy. Arch Gen Psychiatry. 1964;10:561–71.
- Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets. 2014;13(10):1804–18.
- Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139(1):81–132. doi:
- Moore MT, Fresco DM. Depressive realism: a meta-analytic review. Clin Psychol Rev. 2012;32(6):496–509. doi:
- Shestyuk AY, Deldin PJ. Automatic and strategic representation of the self in major depression: trait and state abnormalities. Am J Psychiatry. 2010;167(5):536–44. doi:
- Horst S, Chao A, Rosen M, Nohl A, Duley C, Wagnon JH, et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig Dis Sci. 2015;60(2):465–70. doi:
- Bortolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS. The Involvement of TNF-alpha in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr Neuropharmacol. 2015;13(5):558–76. doi:
- Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. J Crohns Colitis. 2016.
- Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12(8):1246–56 e6. doi:
- Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9. doi:
Source: PubMed